Sun Pharmaceutical has won a trademark dispute in Bombay High Court, which barred Meghmani Lifesciences from using the drug mark “Esiraft.” The court accepted Sun’s claim that Meghmani’s “Esiraft” is visually and phonetically similar to Sun’s “Raciraft,” creating a strong likelihood of consumer confusion and amounting to infringement and passing off.
The Bombay High Court has barred a Navi Mumbai drugmaker from using the brand names “Absun” and “Absun Pharma,” siding with Sun Pharmaceutical Industries. In a long-running trademark dispute, the court ruled the competing names are deceptively similar to Sun Pharma’s established marks, potentially confusing consumers. The verdict effectively ends the decade-long legal battle.
Your news, in seconds
Get the Beige app — every story in 60 words, updated hourly. Free on iOS & Android.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
